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A B S T R A C T
Purpose: Several studies suggest that vagal nerve stimulation (VNS) is an effective treatment for
medication-resistant epileptic patients, although patients’ medication was usually modiﬁed during the
assessment period. The purpose of this prospective study was to evaluate the long-term effects of VNS, at
18 months of follow-up, on epileptic patients who have been on unchanged antiepileptic medication.
Methods: Forty-three patients underwent a complete epilepsy preoperative evaluation protocol, and
were selected for VNS implantation. After surgery, patients were evaluated on a monthly basis,
increasing stimulation 0.25 mA at each visit, up to 2.5 mA. Medication was unchanged for at least 18
months since the stimulation was started. The outcome was analysed in relation to patients’ clinical
features, stimulation parameters, epilepsy type, magnetic resonance imaging (MRI) results, and history
of prior brain surgery.
Results: Of the 43 operated patients, 63% had a similar or greater than 50% reduction in their seizure
frequency. Differences in the responder rate according to stimulation intensity, age at onset of epilepsy,
duration of epilepsy before surgery, previous epilepsy surgery and seizure type, did not reach statistical
signiﬁcance. Most side effects were well tolerated.
Conclusions: 62.8% of our series of 43 medication-resistant epileptic patients experienced a signiﬁcant
long-term seizure reduction after VNS, even in a situation of on unchanged medical therapy. Patient
characteristics predictive of VNS responsiveness remain subject to investigation. Controlled studies with
larger sample sizes, on VNS for patients with medication-resistant epilepsy on unchanged medication,
are necessary to conﬁrm VNS efﬁcacy for drug-resistant epilepsy, and to identify predictive factors.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Several studies have suggested that vagal nerve stimulation
(VNS) is an effective therapy for reducing seizure frequency in
medication resistant epileptic patients, who are poor candidates
for resection or in those in whom resection has failed.2,4,5,8–
10,12,13,29 In previous published series, VNS achieved a 50% greater
seizure frequency reduction in 50–60% of implanted patients after
1 year of therapy.18,19,25 In those studies, concomitant changes in
antiepileptic drugs were allowed.3,4,13,22,23,37,51 A progressive
decline in seizure frequency is usually found during the ﬁrst year
of stimulation, and it remains uncertain if the progressive
improvement seen with longer VNS exposures might be ascribable
to a modiﬁcation in the medical therapy, rather than to sustained* Corresponding author at: Division of Neurosurgery, University Hospital La
Princesa, C/Diego de Leo´n 32, 28006 Madrid, Spain. Tel.: +34 915202200/17430;
fax: +34 914013582.
E-mail address: cristinatorresdiaz@yahoo.es (C.V. Torres).
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.09.008VNS.14,16,17,30 To date, there is only one study performed in the
adult population on unchanged medical therapy during the
postoperative evaluation.30 In this study, the patients’ outcome
was assessed 1 year after surgery. It has been reported that no
speciﬁc antiepileptic drugs seem to have additive antiseizure
effects with VNS; however, to precisely evaluate the net impact of
vagal stimulation in operated patients, it is essential to maintain
stable doses of the administered drugs. The purpose of this study
was to prospectively evaluate the long-term effects of VNS, at 18
months of follow-up, on epileptic patients who have been on
unchanged antiepileptic medication.
2. Materials and methods
Forty-three adult patients with medication-resistant epilepsy
were treated with VNS in our institution, from 2005 to 2009.
Preoperatively, all patients had undergone a complete preopera-
tive epilepsy evaluation protocol,39,47 which includes videoelec-
troencephalogram (VEEG), 1.5 T magnetic resonance imaging
(MRI), interictal single-photon emission computed tomographyvier Ltd. All rights reserved.
Table 2
Differences between types of patients undergoing vagal nerve stimulation at our
institution, at 2 years from surgery.
Patients’ features Responders Non-responders
Mean seizure frequency
reduction
69.8% (18.1) 4.3% (13.6)
Mean age at surgery 33 (10.5) years 34 (14.16) years
Mean age at the
epilepsy onset
6.9 (5.8) years 12.8  13.8 years
Mean duration of
epilepsy before surgery
26  9.6 years 21, 8.8 years
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ment. Findings of the presurgical evaluation were discussed at a
multidisciplinary case conference, where decisions were made
about the possibility and type of brain surgery, as well as VNS, or
the need for further investigations.
The implanted system was the 1Cyberonics VNS TherapyTM,
and the surgical technique has been previously described23,37; all
of the implantations were performed by the same surgeon. Chronic
stimulation was activated 15 days after the surgery. The initial
parameters were: 0.25 mA; 20 Hz, 250 ms, 30 s stimulus on-time
and 5 min stimulus off-time. Patients were evaluated on a monthly
basis, increasing stimulation by 0.25 mA at each visit up to 2.5 mA,
if there were no major adverse effects (except for one case, in
whom the stimulation was set at 2.75 mA). When patients reached
this level of stimulation, they were reviewed every 6 months,
except for those that needed more frequent follow-ups due to
medical reasons.
In the postoperative visits, seizure frequency, side effects, and
other signiﬁcant information reported by family members and
caregivers, was collected. Seizures were classiﬁed, according to
their frequency, as daily seizures if the patient had 7 or more per
week, as weekly seizures if the patient had from 1 to 6 a week, and
as monthly seizures if the patient had less than four per month.
Responders were deﬁned as having a 50% or greater reduction in
seizure frequency with respect to the mean seizure frequency
during the last year before the implantation of VNS. Changes in the
pharmacological treatment were not allowed during the ﬁrst 18
months of postoperative follow-up.
Group mean differences in percentage of reductions in seizure
frequency were tested non-parametrically if variables were not
distributed normally, and using the paired Student’s t-test for
normal distributions. Normality was evaluated using the Kolmo-
gorov–Smirnov test. The software SPSS 17.0 was used for statistical
analysis. The signiﬁcance level was set at p = 0.05. Results are
shown as the mean  SEM, except where otherwise indicated. This
study was approved by the local ethics committee board.
3. Results
Clinical characteristics of the patients are shown in Table 1. The
study involved 22 women and 21 men. The mean age at epilepsy
onset was 9 (9.9) years, and the mean age at implantation was 34
(11.8) years. The majority of patients had daily multifocal or
generalised seizures (51%), and 12 patients had undergone a previous
surgery for epilepsy, which proved unsuccessful.
The mean seizure frequency reduction at 18 months follow-up
was 46.6% (35.5) (Table 2). Twenty-seven of the 43 patientsTable 1
Patient demographics.
Epilepsy type (n)
Generalised or multifocal epilepsy 22
Temporal lobe epilepsy 5
Frontal lobe epilepsy 13
Other extratemporal locations 3
Baseline seizure rate (mean)
Daily seizures (n) 34
Weekly seizures (n) 5
Monthly seizures (n) 4





Duration of epilepsy before surgery (mean years) 25 years (9.6)included in the analysis (63%) were responders. Among the 27
responders, seven patients (16% of the total sample), had a greater
than 90% seizure frequency reduction. Four of these 7 patients with
90% of seizure reduction had frontal seizures (one of them was
seizure-free), one patient had occipital-temporal seizures, and 2
patients had generalised seizures. Clinical features of responders and
non-responders are summarised in Table 2.
Patients and caregivers reported other positive aspects derived
from VNS: Ten patients referred to a reduction in seizure duration
and severity; three patients reported a disappearance of the
generalised tonic–clonic seizures, with persistence of the other
seizure types; ten patients with mental retardation showed an
improvement in alertness; and one patient experienced a non-
quantiﬁed weight loss. One patient, however, reported an increase
in the duration and intensity of his seizures.
Twenty-two patients experienced side-effects. The most
common were mild, consisting in hoarseness, neck tingling or
occasional coughing at the time when the signal was on, all of
which were usually well tolerated. Two patients had intermittent
dyspnoea, and another patient experienced occasional episodes of
dysphagia with stimulation. Irritability was reported by two
families, in the context of a general improvement in the level of
alertness. Five had severe side effects, requiring their VNS
generators to be inactivated or explanted. Three of the 5 patients
that stopped receiving stimulation had been responders. Reasons
for explantation were infection in two patients, and odynophagia,
in one patient. One patient had an exacerbation of a previous
behaviour disturbance, with severe aggressiveness, which im-
proved when the stimulator was inactivated. Seizure reduction
was maintained after the stimulation was stopped. Another
stimulator was removed at family request, owing to a persistent
abdominal pain.
For the 38 patients that continued receiving stimulation,
intensity ﬂuctuated between 0.5 mA and 2.75 mA. Mean seizureFig. 1. Seizure reduction rate by stimulation intensity, in our series of patients on
unchanged medication undergoing vagal nerve stimulation for medication-
resistant epilepsy, at the second year follow-up. mA, miliamperes.
Fig. 2. Seizure frequency reduction rate by type of epilepsy, in our cohort of patients
treated with vagal nerve stimulation for medication-resistant epilepsy, on
unchanged medication, at the second year follow-up.
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Fig. 1. Two patients receiving stimulation at 0.25 mA, obtained a
greater than 90% reduction in the frequency of their seizures. The
responder rate for patients at 2 mA was 71% (17 out of 24
patients, whereas it was 53% for those at <2 mA (7 out of 19
patients).
The relationship between the clinical outcome and the intensity
of stimulation, epilepsy type and location, and frequency did not
reach statistical signiﬁcance. Patients with generalised epilepsy
had a mean seizure frequency reduction of 49.4  34.8%, and those
with focal epilepsy, 44.5  35.6%. Among them, patients with
temporal epilepsy had a seizure reduction rate of 63.0  34.8%
(Fig. 2). We analysed the percentage of responders by epilepsy
location, and we found that 4 out of 5 (80%) of the patients with
temporal lobe epilepsy, 15 out of 22 (74%) of the patients with
generalised epilepsy, 6 out of 13 (46%) of the patients with frontal
epilepsy, and 1 out of 3 (33%) of those with other extratemporal
seizures, were responders.
Twenty-three out of 34 (67%) patients with daily seizures
responded to stimulation, whereas those with monthly or 5 weekly
seizures had a responder rate of 50% (2 out of 5, and 2 out of 4
patients, respectively). Eight out of 12 (66%) patients with a history
of previous epilepsy surgery were responders, while of those
without a previous operation, 10 out of 21 (50%) responded to
stimulation.
4. Discussion
Given the complexity and degree of disability of patients
treated with VNS, most of the studies have allowed modiﬁcation of
the patients’ antiepileptic medication types and doses after the
implantation32,33; this may signiﬁcantly affect the analysis of the
results.36,41,44–46,48,49 To our knowledge, this is the only long-term
prospective study that has been performed on VNS for adults with
no changes in the medical treatment during the follow-up (6).
In our series, the percentage of epileptic patients that achieved
a 50% or greater seizure frequency reduction, 18 months after VNS
implantation, was 63%, and the mean reduction in seizure
frequency was 46.6%. In various published series, an equal or
higher than 50% reduction in seizure frequency was achieved in
about 50% of patients (18.4–67%), and the mean reduction in the
frequency of seizures was 42.8% (range 28–66%).7,15,21,35,43,53 Inthe only study to date, performed on an adult population where
medication type and doses were held totally constant during the
postoperative period, the median reduction in seizure frequency, 1
year after the stimulation was started, was 63%.30
The implantation of VNS implies frequent visits to clinic and
therefore the possibility of a more careful adjustment of medical
therapy; moreover, patients might derive an improvement in
seizure frequency from the administration of new drugs. On the
other hand, our results are similar to those obtained in
institutions with extensive experience in epilepsy and vagal
stimulation, suggesting that changes in medication therapy
during the period of adjustment of parameters do not appear to
beneﬁt patients.30 The absence of medication changes, which
can interfere with the evaluation of seizure frequency and side
effects, may be helpful in optimising stimulation settings and
thus, in improving response rates. Moreover, as most neurolo-
gists and patients hope to decrease the number of medications
after VNS placement, it is possible that a reduction in the
medication regime might have had a detrimental effect on
patients undergoing VNS.
There are several studies suggesting that high intensity of
stimulation corresponds to better outcome, although some other
authors consider the time of exposure to the treatment, and not the
intensity of stimulation, the key factor that leads to appropriate
responses.15,18,26,30,40 In our series, the relationship between the
clinical outcome and the intensity of stimulation was indepen-
dently analysed for the duration of stimulation, since the outcome
was uniformly considered at 18 months. Outcome differences
according to intensity of stimulation were not statistically
signiﬁcant, and there were also some very satisfactory results
besides the usual therapeutic values of stimulation.31,34 Other than
frontal focal epilepsy and younger age at the VNS implantation,
have also been considered positive predictive factors for VNS
response in various studies,26,30 although no deﬁnite conclusions
have been drawn.23,26–28 In our series, 15 out of 22 patients with
generalised epilepsy were responders, and 4 of the 7 patients that
obtained a frequency reduction of more than 90% had frontal
epilepsy. It is also of note that our patients’ mean epilepsy duration
at the time of surgery (25 years), was very high.30,42 Finally, the
existence of a previous surgery has been suggested as a negative
predictive factor after VNS.4 It is of importance to conﬁrm these
results, because they might substantially modify VNS patient
selection. In our series, 8 out of 12 patients with a previous surgery
attained satisfactory results from stimulation. Further studies on
VNS for epileptic patients on unchanged medication are needed to
elucidate which are the main predictive factors of responsiveness
to VNS.
The impact of the VNS in other domains of interest has been
documented in several studies.20,42,43 The improvement in mood
and cognitive performance has led to indicate VNS for patients
with chronic depression, although later results have been
conﬂicting.42,43 In our series, a positive effect on alertness has
been observed in almost a quarter of the patients. Reduction in
seizure frequency and independent mechanisms for regulation of
various centroencephalic nuclei have been implicated in these
processes, although they have not been yet elucidated.23,42,43,50 It
must be said that, occasionally, the improvement of the level
of alertness has not been linked to an improvement in the
quality of life, since patients are more aware of the limitations of
their illness. In our series, previous behaviour disorders were
exacerbated.1,6,22,23,52,54
There are limitations to our study, since a control group was not
included in the analysis. It is difﬁcult to compare previously
reported series of patients with drug-resistant epilepsy under the
best medical treatment with our series because of differences
in the deﬁnition of drug-resistant epilepsy and patient
E. Garcı´a-Navarrete et al. / Seizure 22 (2013) 9–1312characteristics.11,55–58 In previous reports, the remission rate for
epileptic patients that have been resistant to at least two
antiepileptic drugs oscillates between 4 and 5% per year, and
around 50% of patients might be responders in the long
term.11,24,38,54,55 VNS, as any chronic implanted medical device,
requires unambiguous positive evidence for therapeutic superior-
ity over conservative treatment in regards to costs, risks, and
adverse effects. Despite the fact that our study eliminates the
confounding factor of medication changes during the assessment
period after VNS implantation, there is a need for long-term
controlled prospective studies with patients under VNS, and
without changes in medication, to conﬁrm our results.
5. Conclusions
62.8% of our series of 43 medication-resistant epileptic patients
experienced a signiﬁcant long-term seizure reduction after VNS,
even in a situation of unchanged medical therapy. Patient
characteristics predictive of VNS responsiveness remain subject
to investigation. It is necessary to perform controlled studies with a
larger number of subjects on unchanged antiepileptic medication
to draw deﬁnitive conclusions
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